ProBioGen AG

ProBioGen AG is a biopharmaceutical contract development and manufacturing organization (CDMO) that specializes in cell line engineering, process development, and GMP manufacturing, focusing on advanced therapies and vaccines. ProBioGen AG operates as a contract development and manufacturing organization (CDMO) in the biopharmaceutical sector, with its headquarters located in Berlin, Germany. The company was acquired by Minapharm Pharmaceuticals, which now holds a 95% stake as of June 16, 2010, marking a pivotal shift in ownership. The leadership team includes Lutz Hilbrich, Marc Bantel, and Wieland Wolf.

ProBioGen has successfully raised a total of EUR 30. 40 mn through funding rounds, with the most recent being a TRADE SALE amounting to EUR 30. 40 mn from Minapharm Pharmaceuticals, which underscores the company’s strong market positioning and investment interest. ProBioGen AG specializes in providing comprehensive Contract Development and Manufacturing Organization (CDMO) services tailored for the biopharmaceutical sector.

Their core offerings encompass cell line engineering, process development, and Good Manufacturing Practice (GMP) manufacturing, focusing on biopharmaceuticals, viral vectors, and vaccines. Leveraging proprietary technologies such as CHO. RiGHT® for producer cell lines and DirectedLuck® for transposase systems, ProBioGen optimizes the manufacturing processes to enhance product yield and quality. The company caters to a diverse client base that includes biotechnology and pharmaceutical firms globally, particularly in regions such as North America, Europe, and Asia.

By addressing critical needs in biopharmaceutical production, ProBioGen enhances the development pathways for therapeutic proteins and advanced therapies, ensuring timely delivery and adherence to stringent quality standards. ProBioGen generated revenue of EUR 49,254,819. 30 in the most recent year, 2023, with an EBITDA of EUR 9,883,902. 20.

The firm's revenue generation relies on customized service agreements that may include project-based pricing for specific development and manufacturing services, as well as ongoing collaborations for extended projects. Their framework for transactions often involves upfront fees coupled with milestone payments based on the successful completion of defined project stages. Specific flagship services, such as their proprietary CHO. RiGHT® production system and GMP manufacturing capabilities for viral vaccines, command premium pricing due to their specialized nature and the high demand for reliable biopharmaceutical development.

The financial structure of these agreements is designed to foster long-term relationships with clients while ensuring the delivery of high-quality products and services. ProBioGen AG is focused on enhancing its product offerings, with plans for the development of new biopharmaceutical manufacturing technologies aimed at improving efficiency and yields. The company is also looking to expand its reach into emerging markets in Asia and South America by 2025, capitalizing on the growing demand for biopharmaceuticals in these regions. Recent funding will support these initiatives by enabling further investment in R&D and scaling up production capabilities.

The strategic acquisition by Minapharm Pharmaceuticals positions ProBioGen to leverage additional resources and expertise to accelerate its growth trajectory.